Inclusion Criteria:

Each patient must meet all of the following inclusion criteria to be enrolled in the
study:

- Refractory advanced solid tumor that has failed standard therapy.

- ECOG PS ≤ 2

- Voluntary written informed consent before performance of any study-related procedure
not part of normal medical care, with the understanding that consent may be withdrawn
by the subject at any time without prejudice to future medical care.

- Female subject is either post-menopausal or surgically sterilized or willing to use
an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine
device, diaphragm with spermicide, condom with spermicide, or abstinence) for the
duration of the study.

- Male subject agrees to use an acceptable method for contraception for the duration of
the study.

- Cardiac ejection fraction is more than 45%

Exclusion Criteria:

- Patient has a platelet count of <100 x 109/L within 14 days before enrollment.

- Patient has an absolute neutrophil count of ANC <1.0 x 109/L within 14 days before
enrollment.

- Patient has a calculated or measured creatinine clearance of <30 mL/minute within 14
days before enrollment.

- AST, ALT, total bilirubin > twice the upper limits of normal.

- Received radiation to more than 30% of marrow volume

- Patient has greater than or equal to Grade 2 peripheral neuropathy within 14 days
before enrollment.

- Myocardial infarction within 6 months prior to enrollment or has New York Heart
Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled
angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
of acute ischemia or active conduction system abnormalities. Prior to study entry,
any ECG abnormality at Screening has to be documented by the investigator as not
medically relevant.

- Patient has hypersensitivity to sunitinib, bortezomib, boron or mannitol.

- Uncontrolled hypertension

- History of venous thromboembolic events.

- Female subject is pregnant or breast-feeding. Confirmation that the subject is not
pregnant must be established by a negative serum Beta-human chorionic gonadotropin
(Beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not
required for post-menopausal or surgically sterilized women.

- Patient has received other investigational drugs with 14 days before enrollment

- Serious medical or psychiatric illness likely to interfere with participation in this
clinical study.

- Hemorrhagic tendency of the tumor